Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial

Yongxiang Xia, Weiwei Tang, Xiaofeng Qian, Xiangcheng Li, Feng Cheng, Ke Wang, Feng Zhang, Chuanyong Zhang, Donghua Li, Jinhua Song, Hui Zhang, Jie Zhao, Aihua Yao, Xiaofeng Wu, Chen Wu, Gu‐Wei Ji, Xi-Sheng Liu, Feipeng Zhu, Lang Qin, Xuan Xiao, Zhenhua Deng, Xiangyi Kong, Si Li, Yangyang Yu, Wenjing Xi, Wanglong Deng, Chuang Qi, Hanyuan Liu, Liyong Pu, Ping Wang, Xuehao WangJournal for ImmunoTherapy of Cancer 2022 · DOI

Abstract: NCT04297202. This Phase II clinical trial investigated the safety and efficacy of a perioperative regimen combining camrelizumab (a PD-1 inhibitor) and apatinib (a VEGFR2 inhibitor) for patients with resectable hepatocellular carcinoma (HCC). The study demonstrated manageable safety profiles and promising pathological responses. Furthermore, multi-omic profiling identified dendritic cell (DC) infiltration and circulating tumor DNA (ctDNA) as potential biomarkers for predicting treatment response and recurrence risk.

Introduction

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide. While surgical resection is the primary curative intent treatment for resectable cases, the long-term prognosis is often marred by high recurrence rates, with approximately 54% of patients experiencing a relapse within two years post-surgery.

The "perioperative" window—encompassing both neoadjuvant (pre-operative) and adjuvant (post-operative) phases—presents a critical opportunity to improve surgical outcomes. While systemic therapies have transformed the management of advanced HCC, their role in enhancing the efficacy of surgery and preventing recurrence in resectable patients is still being defined. This study evaluates whether combining immunotherapy with anti-angiogenesis therapy can improve pathological responses and reduce post-surgical relapse.

Study Design and Methodology

This single-arm, open-label, Phase II trial (NCT04297202) enrolled patients with surgically resectable HCC to receive a comprehensive perioperative treatment plan.

Study design schema and patient enrollment flow chart.

As illustrated in the study schema, the regimen consisted of:

  • Neoadjuvant Phase: Three cycles of camrelizumab (200 mg every 2 weeks) combined with apatinib (250 mg daily for 21 days), followed by radiological reassessment and hepatectomy.
  • Adjuvant Phase: Eight additional cycles of the same combination therapy starting approximately four weeks after surgery.

To identify biological drivers of treatment success, the researchers employed a multi-omics pipeline, including transcriptomic analysis of the tumor immune microenvironment (TIME) via a 289-gene NanoString panel, longitudinal ctDNA sequencing, and TMT-labeled proteomics to compare responding versus non-responding lesions.

Clinical and Radiological Outcomes

Of the 20 patients recruited, 18 received neoadjuvant therapy and 17 successfully underwent surgical resection. The study reported encouraging pathological and radiological responses.

Waterfall plot of tumor response according to mRECIST criteria.

Key clinical results included:

  • Pathological Response: Among the 17 patients who underwent surgery, 17.6% (3/17) achieved a Major Pathological Response (MPR), and 5.9% (1/17) achieved a Pathological Complete Response (pCR).
  • Radiological Response: The Objective Response Rate (ORR) was 16.7% per RECIST v1.1. However, when using mRECIST—which specifically accounts for tumor necrosis and viability—the ORR increased to 33.3%, as shown in the waterfall plot above.
  • Survival: At the time of analysis, the 1-year Relapse-Free Survival (RFS) rate was 53.85%.

Multi-omic Biomarker Insights

The integration of multi-omic data provided several key insights into the mechanisms of response and resistance:

  • Dendritic Cells (DCs) as Predictors: High DC infiltration in baseline biopsies was strongly associated with a positive response to neoadjuvant therapy. Post-treatment DC levels also correlated with a lower risk of relapse, suggesting that DCs are essential for priming the T-cell response required for effective immunotherapy.
  • ctDNA Dynamics: Patients who remained ctDNA-positive following adjuvant therapy experienced significantly shorter RFS. Interestingly, responders (MPR/pCR) exhibited a higher mutation burden at baseline, potentially indicating a higher neoantigen load that increases tumor immunogenicity.
  • Metabolic Heterogeneity: Proteomic analysis of multifocal HCC revealed that different lesions within the same patient could respond differently. Non-responding lesions often showed upregulated glucose metabolism (glycolysis) pathways, suggesting metabolic reprogramming as a potential resistance mechanism.

Safety and Tolerability

The perioperative regimen was generally manageable, though not without complications. Grade 3/4 adverse events (AEs) occurred in 16.7% of patients during the preoperative phase (primarily rash and hypertension) and 38.5% during the postoperative phase. Notably, surgeons observed that the neoadjuvant therapy increased surgical difficulty, leading to longer operative times and increased bleeding, which suggests a need for optimized "washout" periods before surgery.

Discussion and Limitations

While the results are promising, the authors acknowledge several limitations, including the small sample size (n=18) and the single-arm design, which precludes a direct comparison with surgery alone. Additionally, the 1-year follow-up period is relatively short for assessing long-term survival in HCC.

Future research should focus on larger randomized controlled trials to validate these findings and refine the use of DC and ctDNA biomarkers to personalize perioperative care for HCC patients.

Summary updated

Abstract

NCT04297202.
BibTeX
@article{xia2022efficacy,
  author = {Yongxiang Xia and Weiwei Tang and Xiaofeng Qian and Xiangcheng Li and Feng Cheng and Ke Wang and Feng Zhang and Chuanyong Zhang and Donghua Li and Jinhua Song and Hui Zhang and Jie Zhao and Aihua Yao and Xiaofeng Wu and Chen Wu and Gu‐Wei Ji and Xi-Sheng Liu and Feipeng Zhu and Lang Qin and Xuan Xiao and Zhenhua Deng and Xiangyi Kong and Si Li and Yangyang Yu and Wenjing Xi and Wanglong Deng and Chuang Qi and Hanyuan Liu and Liyong Pu and Ping Wang and Xuehao Wang},
  title = {{Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial}},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2022},
  doi = {10.1136/jitc-2022-004656},
}
Figure